Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

Merck & Co – known as MSD outside of the US and Canada – and Cyprumed have entered into a partnership aimed at developing ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

Li, president, Merck Research Laboratories. “HRS-5346 ... the industry stares down a wave of generic drugs this year that has made the issue of securing new candidates all the more pressing. However, ...

Merck Life Science South Africa, a leading science and technology company, is excited to announce its participation as a bronze sponsor at Analytica Lab Africa 2025. This major trade fair for ...

Merck & Co. has entered a competitive race for a new type of heart drug ... president of Merck Research Laboratories, in a statement. The frontrunners in the chase, among them Novartis and ...

Dean Li, president of Merck Research Laboratories, told the meeting that ... but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck acquired ...

The trial compared the new subcutaneous pembrolizumab ... global clinical development at Merck Research Laboratories, also highlighted the innovative approach of the subcutaneous pembrolizumab ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong.

Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data sho ...

NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the ...

Li, president, Merck Research Laboratories. “HRS-5346 ... of generic drugs this year that has made the issue of securing new candidates all the more pressing. However, President Trump’s ...